Pfizer To Buy Anacor For $99.25 Per Share In Cash For Transaction Value Of $5.2b
May 16, 2016 at 09:29 AM EDT
Anacor's flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis (eczema).
